MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast period. The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing. The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years. The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.

By product & service, the reagents and kits segment is expected to grow at the highest growth rate during the forecast period

Among the product & service, segment, the reagents and kits segment is expected to grow at the highest CAGR during the forecast period. The factors attributing to the high growth are, the accessibility of a wide range of reagents, the increasing demand for reagents owing to the increasing genotyping test volumes across the globe, and the relatively smaller capital investment required to adopt reagents and kits for genotyping in pharmaceuticals and diagnostic centers.

By technology, the sequencing segment to record the highest CAGR during the forecast period

The sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.

By application, the pharmacogenomics segment is expected to account for the largest share of the genotyping assay market

On the basis of application, the genotyping market is segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment is expected to account for the largest share of the genotyping market during the forecast period. The large share of this segment can be attributed to the increasing use of genotyping to predict the efficiency of drugs during drug development and the growing need to understand the adverse effects of drugs.

By end user, the pharmaceutical and biopharmaceutical companies segment to record the highest CAGR during the forecast period

The pharmaceutical and biopharmaceutical companies segment is expected to witness the highest growth during the forecast period. The increasing demand for pharmacogenomics in the drug discovery and development process and recommendations from the FDA to include genotyping and pharmacogenomics studies in the course of drug discovery have contributed to the growth of this market segment.

North America to account for the largest market size during the forecast period.

North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region, along with an increasing demand from pharmaceutical companies for genotyping products and rising investments by government bodies, are responsible for the large share of the North American genotyping market.

Market Dynamics

Driver: Technological Advancements and Decreasing Prices of DNA Sequencing

Technical advancements have allowed for miniaturization, automation, and reduced overall costs, as well as operational flexibility and the incorporation of multi-parameter testing. All of these have greatly helped increase the applications and convenience of DNA sequencing, allowing physicians to focus on high-level decision-making such as identifying and prioritizing drug targets through various genotyping studies. This has directly boosted the uptake of PCR, sequencing, capillary electrophoresis, and microarray technologies in fields such as drug discovery and clinical research. In addition to this, technological advances in DNA sequencing such as NGS have allowed for rapid, accurate sequencing, allowing for high productivity. This has also reduced the cost of DNA sequencing, reducing the overall cost of genomic and genotyping projects by USD 2,500 within a year (Source: National Human Genome Institute).

Restraint: High Cost of Equipment Used In Genotyping

Instruments required to carry out genotyping tests are very expensive, and high capital investment is required for their installation. For instance, qPCR systems cost ~USD 20,000�30,000, while dPCR systems cost USD 65,000�USD 70,000 for manual dPCR and crest at USD 100,000 for automated dPCR. NGS sequencers can cost between USD 19,900 to USD 1 million. Illumina�s new sequencers�NovaSeq 5000 and NovaSeq 6000�are priced at about USD 850,000 and USD 985,000, respectively. Genotyping instruments are equipped with advanced features and functionalities, making them highly priced. Pharmaceutical companies and research laboratories require a number of such systems, creating the need for significant investments for procuring multiple, high-cost genotyping instruments. Maintenance costs and several other indirect expenses, such as sample and labor costs, also result in an overall increase in the total cost of ownership of these instruments. As a result, the installation/expansion of advanced research facilities such as NGS technology is hampered in academic and research institutes in developing nations across Asia, the Middle East, and Africa.

Opportunity: Increasing Application Areas of Genotyping

Genotyping platforms have several potential application areas such as pharmacogenomics, diagnostic research, personalized medicine, and forensics. Furthermore, this technology is also apt for a range of veterinary needs, food safety and quality, and environmental testing in remote areas and industrial settings. At present, human diagnostics and pharmacogenomics offer significant marker potential as these segments require rapid genotyping analysis on a large scale due to the need for better treatment options and high disease prevalence. Technologies such as NGS are being adapted to this purpose, with companies such as QIAGEN and Freenome (US) partnering to develop NGS-based tests for precision medicine.

Challenge: Data Management in Genotyping Research

Quantitative and qualitative genotyping studies generate massive volumes of data. Earlier, this data was stored manually; however, this presented a major challenge as up to gigabytes of data could be generated within a few hours. Technological advancements have enabled automation in the data storage process by creating databases for storing genotyping data. However, understanding the full potential of such datasets is another hurdle for technicians. Major genomic databases include the Conserved Domain Database (CDD), Database of Genomic Structural Variation (dbVar), Database of Genotypes and Phenotypes (dbGaP), Database of Short Genetic Variations (dbSNP), Genetic Testing Registry (GTR), and Genome Reference Consortium (GRC). These databases are still working on ways to streamline data importing and storage queried during multiple sequencing experiments using a common web interface.

Scope of the Report

Report Metric Details Market size available for years 2016�2023 Base year considered 2017 Forecast period 2018�2023 Forecast units Million (USD) Segments covered Product & Service, Technology, Application, End User, and Region Geographies covered North America, Europe, APAC, MEA, and Latin America Companies covered Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

The research report categorizes the genotyping assay to forecast the revenues and analyze the trends in each of the following sub-segments:

Genotyping Market, By Product & Service

Reagents & Kits

Genotyping Services

Instruments Sequencers & Amplifiers Analyzers

Bioinformatics Software Services



Genotyping Market, By Technology

PCR Real-time PCR Digital PCR

Microarrays

Sequencing NGS Pyrosequencing Sanger Sequencing

Capillary Electrophoresis Amplified Fragment Length Polymorphism Restricted Fragment Length Polymorphism Single-stranded Conformation Polymorphism

MALDI-TOF

Other Technologies (Allele-specific Oligonucleotide (ASO) Probes and Fluorescence In Situ Hybridization (FISH))

Genotyping Market, By Application

Pharmacogenomics

Diagnostic & Personalized Medicine

Agricultural Biotechnology

Animal Genetics

Other Applications (Prenatal Testing, Human Forensics, Microbial Genomic Studies, and Aquaculture Breeding Studies)

Genotyping Market, By End User

Pharmaceutical and Biopharmaceutical Companies

Diagnostic and Research Laboratories

Academic Institutes

Other End Users (Animal and Aqua Genetics Companies, Greenhouses, and Farms)

Genotyping Market, by Region

North America US Canada

Europe Germany UK France Italy Spain Rest of Europe

Asia Pacific China Japan India Rest of Asia Pacific

Latin America

Middle East and Africa

Key Market Players

Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

Illumina is the leading player in the genotyping market. The company led the sequencing market with its flagship NGS platforms�iSeq 100 system (launched in January 2018), NovaSeq 6000, HiSeq Series, MiSeq Series, NextSeq 500, and HiSeq X Ten & HiSeq X Five. Illumina also provides reagents such as TruSeq sample preparation kits, TruSeq SBS sequencing kits, and other sequencing reagents, along with sequencing services such as whole-genome sequencing, human whole-exome sequencing, de novo sequencing, custom-targeted resequencing, gene expression using random-primed RNA sampling, and other related services.

Recent Developments

In May 2018, Agilent technologies opened a new logistics center in Texas to increase its capacity for house inventory and to fulfill the growing demand for NGS products from its genomics group.

In March 2018, Danaher Corporation acquired Integrated DNA Technologies Inc. (US). This acquisition strengthened Danaher�s Life Sciences platform. IDT will operate as a standalone operating company and brand within Danaher Corporation.

In January 2018, Thermo Fisher Scientific signed a partnership with Illumina (US) that enabled Illumina to sell the Ion AmpliSeq technology to researchers who conduct scientific studies using Illumina�s next-generation sequencing (NGS) platforms.

In January 2018, Illumina launched the iSeq 100 Sequencing System.

In January 2018, Thermo Fisher Scientific launched the Ion GeneStudio S5 Series Instrument.

Critical questions the report answers:

Where will all these developments take the industry in the long term?

What are the upcoming trends for the genotyping market?

Which segment provides the most opportunity for growth?

Who are the leading players operating in this market?

What are the opportunities for new market entrants?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst